It’s March 19, and Erica Barnell, MD/PhD ’23, knows her company’s position could change dramatically soon. Barnell, co-founder and chief medical and science officer of Geneoscopy , is awaiting a decision letter from the Food and Drug Administration (FDA) for approval of ColoSense, the company’s noninvasive, multitarget RNA-based screening test for colorectal cancer. The innovative home test, which received the FDA’s “Breakthrough Device” designation in 2020, demonstrated a high sensitivity and s...